Bahar Moghaddam1, Shelby Marozoff2, Lingyi Li2,3, Eric C Sayre2, J Antonio Aviña- Zubieta2,3,4. 1. Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Arthritis Research Canada, Vancouver, BC, Canada. 3. Experimental Medicine Program, Department of Medicine, Vancouver, BC, Canada. 4. Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Abstract
OBJECTIVE: To investigate all-cause and cause-specific mortality in SLE patients between two time periods, 1997-2005 and 2006-14. METHODS: We used an administrative health database from the province of British Columbia, Canada to match all incident SLE patients to 10 non-SLE individuals on sex, age and index date. Cohorts were divided into two subgroups, according to diagnosis year: early cohort 1997-2005 and late cohort 2006-14. The outcome was death [all-cause, renal disease, cancer, infection, cardiovascular disease (CVD) and other]. Hazard ratios (HR) and 95% CIs were estimated using univariate and multivariable Cox models. RESULTS: Among 6092 SLE patients and 60 920 non-SLE individuals, there were 451 and 1910 deaths, respectively. The fully adjusted all-cause mortality HR (95% CI) in the overall SLE cohort was 1.85 (1.66, 2.06), with no statistically significant improvement between early and late cohorts [1.95 (1.69, 2.26) vs 1.74 (1.49, 2.04)]. There was excess mortality from renal disease [3.04 (2.29, 4.05)], infections [2.74 (2.19, 3.43)] and CVD [2.05 (1.77, 2.38)], but not cancer [1.18 (0.96, 1.46)], in the overall SLE cohort. There was no statistically significant improvement in cause-specific mortality between early and late cohorts for renal disease [3.57 (2.37, 5.36) vs 2.65 (1.78, 3.93)], infection [2.94 (2.17, 3.98) vs 2.54 (1.84, 3.51)] and CVD [1.95 (1.60, 2.38) vs 2.18 (1.76, 2.71)]. There was no increase in cancer-related mortality in either cohort [1.27 (0.96, 1.69) vs 1.10 (0.82, 1.48)]. CONCLUSION: This population-based study demonstrates a persisting mortality gap in all-cause and cause-specific deaths in SLE patients, compared with the general population.
OBJECTIVE: To investigate all-cause and cause-specific mortality in SLE patients between two time periods, 1997-2005 and 2006-14. METHODS: We used an administrative health database from the province of British Columbia, Canada to match all incident SLE patients to 10 non-SLE individuals on sex, age and index date. Cohorts were divided into two subgroups, according to diagnosis year: early cohort 1997-2005 and late cohort 2006-14. The outcome was death [all-cause, renal disease, cancer, infection, cardiovascular disease (CVD) and other]. Hazard ratios (HR) and 95% CIs were estimated using univariate and multivariable Cox models. RESULTS: Among 6092 SLE patients and 60 920 non-SLE individuals, there were 451 and 1910 deaths, respectively. The fully adjusted all-cause mortality HR (95% CI) in the overall SLE cohort was 1.85 (1.66, 2.06), with no statistically significant improvement between early and late cohorts [1.95 (1.69, 2.26) vs 1.74 (1.49, 2.04)]. There was excess mortality from renal disease [3.04 (2.29, 4.05)], infections [2.74 (2.19, 3.43)] and CVD [2.05 (1.77, 2.38)], but not cancer [1.18 (0.96, 1.46)], in the overall SLE cohort. There was no statistically significant improvement in cause-specific mortality between early and late cohorts for renal disease [3.57 (2.37, 5.36) vs 2.65 (1.78, 3.93)], infection [2.94 (2.17, 3.98) vs 2.54 (1.84, 3.51)] and CVD [1.95 (1.60, 2.38) vs 2.18 (1.76, 2.71)]. There was no increase in cancer-related mortality in either cohort [1.27 (0.96, 1.69) vs 1.10 (0.82, 1.48)]. CONCLUSION: This population-based study demonstrates a persisting mortality gap in all-cause and cause-specific deaths in SLE patients, compared with the general population.
Authors: J N Katz; J Barrett; M H Liang; A M Bacon; H Kaplan; R I Kieval; S M Lindsey; W N Roberts; D M Sheff; R T Spencer; A L Weaver; J A Baron Journal: Arthritis Rheum Date: 1997-09
Authors: Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke Journal: J Autoimmun Date: 2013-02-12 Impact factor: 7.094
Authors: S Bernatsky; J-F Boivin; L Joseph; S Manzi; E Ginzler; D D Gladman; M Urowitz; P R Fortin; M Petri; S Barr; C Gordon; S-C Bae; D Isenberg; A Zoma; C Aranow; M-A Dooley; O Nived; G Sturfelt; K Steinsson; G Alarcón; J-L Senécal; M Zummer; J Hanly; S Ensworth; J Pope; S Edworthy; A Rahman; J Sibley; H El-Gabalawy; T McCarthy; Y St Pierre; A Clarke; R Ramsey-Goldman Journal: Arthritis Rheum Date: 2006-08
Authors: Marko Yurkovich; Kateryna Vostretsova; Wenjia Chen; J Antonio Aviña-Zubieta Journal: Arthritis Care Res (Hoboken) Date: 2014-04 Impact factor: 4.794
Authors: Sasha Bernatsky; Rosalind Ramsey-Goldman; Michelle Petri; Murray B Urowitz; Dafna D Gladman; Paul R Fortin; Edward H Yelin; Ellen Ginzler; John G Hanly; Christine Peschken; Caroline Gordon; Ola Nived; Cynthia Aranow; Sang-Cheol Bae; David Isenberg; Anisur Rahman; James E Hansen; Yvan St Pierre; Ann E Clarke Journal: J Rheumatol Date: 2018-01-15 Impact factor: 4.666
Authors: Elizabeth V Arkema; Andreas Jönsen; Lars Rönnblom; Elisabet Svenungsson; Christopher Sjöwall; Julia F Simard Journal: BMJ Open Date: 2016-01-04 Impact factor: 2.692
Authors: Irene E M Bultink; Frank de Vries; Ronald F van Vollenhoven; Arief Lalmohamed Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580
Authors: Radjiv Goulabchand; Alain Makinson; Jacques Morel; Philine Witkowski-Durand-Viel; Nicolas Nagot; Paul Loubet; Camille Roubille; Danièle Noel; David Morquin; Kim Henry; Thibault Mura; Philippe Guilpain Journal: Ann Med Date: 2022-12 Impact factor: 5.348